Because HHV-6 has low virulence [33] and infects CD4+ T cells, macrophages, and dendritic cells [14], [15], [34], [35], recombinant HHV-6 vectors have been expected to be useful in gene therapy of HIV infection and cancer. Here, CD4 is linked to cancer.